Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeR/R large B-cell lymphomaLarge B-cell lymphomaCenter for International Blood and Marrow Transplant ResearchCytokine release syndromeDuration of responseLiso-celData cutoffRisk of cytokine release syndromeCAR-T cell productsDuration of response rateHigh-risk disease featuresMedian duration of responseReal-world population of patientsB-cell lymphomaTreated with corticosteroidsCAR+ T cellsMarrow Transplant ResearchT cell productionStudy of US patientsPopulation of patientsOne-time infusionReal-world populationReal-world studyCellular therapy registry